Skip to content

HomeCompanies & research
CompaniesExplore European Tech
ResearchAll published research
ThemesExplore the industries
Events & EarningsDates to follow
AboutOur purpose & approach

Join free Log in

Research

Research & articles Research Notes Company updates

Search research or companiesClear filters

CompanyCountryTechnologyPublication yearOrder

Official announcements retain their original headline and source language.

23 results

Company updateSep 28, 2026

GENFIT Reports First-Half 2026 Financial Results and Provides Corporate Update

GENFIT S.A.Company newsroom

Company updateSep 14, 2026

GENFIT Advances Nangibotide in Phase 2 Clinical Investigation in ACLF

GENFIT S.A.Company newsroom

Company updateSep 11, 2026

GENFIT to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris

GENFIT S.A.Company newsroom

Company updateSep 10, 2026

GENFIT to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

GENFIT S.A.Company newsroom

Company updateSep 9, 2026

GENFIT Highlights Long-Term Commercial Opportunity for its MASH Diagnostics Technology

GENFIT S.A.Company newsroom

Company updateSep 3, 2026

GENFIT to Host Virtual KOL Event Focused on MASH Diagnostics on September 9, 2026

GENFIT S.A.Company newsroom

Company updateJul 8, 2026

Genfit: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

GENFIT S.A.Company newsroom

Company updateJul 2, 2026

GENFIT Announces U.S. Medicare Coverage and Future Reimbursement for NASHnext®, a Non-Invasive Diagnostic Technology to Identify Patients with At-Risk MASH

GENFIT S.A.Company newsroom

Company updateJun 23, 2026

GENFIT: Positive Phase 1b Data with GNS561 in Combination Therapy in Heavily Pretreated Patients with Cholangiocarcinoma

GENFIT S.A.Company newsroom

Company updateJun 15, 2026

GENFIT: June 15, 2026 Combined Shareholders Meeting Results

GENFIT S.A.Company newsroom

Company updateJun 8, 2026

GENFIT: NASHnext®, Powered by GENFIT's Non-invasive Diagnostic Technology NIS4®, Launched via Labcorp’s OnDemand Offering for Identification of At-Risk MASH

GENFIT S.A.Company newsroom

Company updateMay 25, 2026

GENFIT Highlights Broad Scientific and Strategic Presence at EASL Congress 2026

GENFIT S.A.Company newsroom

Company updateMay 21, 2026

GENFIT Reports First Quarter 2026 Financial Information and Provides a Corporate Update

GENFIT S.A.Company newsroom

Company updateMay 11, 2026

GENFIT Annual Combined General Meeting of June 15, 2026 — Availability of Preparatory Documents

GENFIT S.A.Company newsroom

Company updateApr 20, 2026

GENFIT: Publication of the 2026 Extra-Financial Report (fiscal year 2025)

GENFIT S.A.Company newsroom

Company updateApr 7, 2026

GENFIT Announces Publication of the 2025 Universal Registration Document

GENFIT S.A.Company newsroom

Company updateApr 2, 2026

GENFIT Reports Full-Year 2025 Financial Results and Provides Corporate Update

GENFIT S.A.Company newsroom

Company updateMar 9, 2026

GENFIT Receives FDA Orphan Drug Designation for NTZ for the treatment of ACLF

GENFIT S.A.Company newsroom

Company updateFeb 26, 2026

GENFIT Reports Fourth Quarter 2025 Financial Information and Provides a Corporate Update

GENFIT S.A.Company newsroom

Company updateFeb 12, 2026

GENFIT to receive US$20M milestone after Ipsen’s Iqirvo® exceeds the US$200M threshold in its first full year of net sales

GENFIT S.A.Company newsroom

Page 1 / 2Next

© 2026 European Tech Equities

X LinkedInSources Privacy Terms

Search companies & research

Search companies & research